Neurona Therapeutics

We're excited to share that Neurona Therapeutics recently partnered with Family Giving Tree to help Bay Area students start the school year with confidence and the tools they need to succeed. Thanks to the generosity and dedication of our team, we collected 31 backpacks - plus additional school supplies - to support students in need. A huge thank you to everyone at Neurona who helped make a meaningful impact in our community! #Neurona #BackpackDrive

Neurona Therapeutics is delighted to announce today’s publication of new peer-reviewed study in Neuron, a Cell Press journal, titled, “Human stem cell-derived GABAergic interneuron development reveals early emergence of subtype diversity and gradual electrochemical maturation”. “In this preclinical study, our team undertook systematic long-term molecular and functional characterization of human interneurons derived from pluripotent stem cells,” said Marina Bershteyn, Director of Discovery Research at Neurona Therapeutics and the study’s lead author. “By precisely specifying high-fidelity MGE interneurons synchronized at a post-mitotic migratory developmental stage before cell administration, we achieved unprecedented, durable control over the fate and function of the xenografted human interneurons.” Link to press release in comments section.

Epilepsy affects more than 3 million Americans－ including 500,000 Californians. Although many people with epilepsy benefit from anti-seizure medications, for about one-third of patients, these medications don't work. With support from a $14 million award from CIRM, Neurona Therapeutics has reached a major milestone in developing its stem cell approach to treating epilepsy. The company announced recently that the first patient has been dosed in a Phase 1/2 clinical trial evaluating NRTX-1001, a cell therapy for adults whose epilepsy affects both sides of the brain and for which anti-seizure drugs have not been effective. CIRM has supported this research from its early discovery stage at UCSF to the current first-in-human clinical trials. Current treatments for drug-resistant epilepsy usually involve invasive surgeries that destroy brain tissue and carry serious, irreversible risks. Patients with epilepsy on both sides of the brain are typically not eligible for these surgeries due to the risk of profound and permanent memory loss. The cell therapy is composed of neurons derived from human embryonic stem cells that inhibit excitatory neurons. When injected into the brain, these cells are designed to calm overactive neurons and reduce seizures without damaging healthy brain tissue. In this trial, patients receive a one-time injection of NRTX-1001 into both sides of the brain. If successful, data from these trials—along with an upcoming Phase 3 study—could support future FDA approval of NRTX-1001 for drug-resistant epilepsy, offering a potential treatment for patients and families affected by this life-altering condition. Read the full blog at https://xmrrwallet.com/cmx.plnkd.in/g9gdxwnD

Neurona Therapeutics is thrilled to announce the dosing of the first patient in its Phase 1/2 clinical trial of NRTX-1001 cell therapy in adults with drug-resistant bilateral mesial temporal lobe epilepsy (MTLE). Additionally, Neurona announced completed enrollment of an expansion cohort of eight patients for its unilateral MTLE study.

Through 24 generous blood donations in partnership with Stanford Blood Center, our Neurona community came together to help save up to 72 lives. This powerful act reflects the heart of who we are: compassionate, purpose-driven, and committed to making a difference beyond the lab. Thank you to everyone who showed up and rolled up your sleeves – your generosity and spirit are a reflection of the values that shape Neurona. #NeuronaBloodDrive #Neurona #RegenerativeMedicine

At Neurona, Pride Month is a time for us to reflect, celebrate, and stand with our LGBTQ+ colleagues, friends, and community. As we celebrate, we also have the responsibility of creating a workplace where diversity and inclusion aren’t just encouraged, they’re expected. We know that progress only happens when we all take ownership in building a more inclusive and equitable workplace, and our company values of integrity, compassion, and accountability are the foundation of how we show up for one another every day. This means actively working to ensure everyone, regardless of gender identity or sexual orientation, always feels respected, heard, and safe being their authentic selves. This Pride, we recommit to listening and learning, because accountability isn’t about getting it perfect. It’s about showing up, doing better, and creating a space where everyone can thrive. #PrideMonth #Pride2025 #Neurona #RegenerativeMedicine

In celebration of Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Heritage Month, we had the opportunity to hear from four colleagues during our monthly happy hour. While sharing personal experiences about tradition and identity, their stories offered insight into how our experiences shape the way we lead and support one another. At Neurona, we believe that strength comes from diversity of backgrounds, perspectives, and experiences across our team. Thank you to those who shared your stories - your openness helps build a more inclusive workplace, and we’re grateful for it. #AANHPIheritagemonth #Neurona

We’re happy to share that Marina Bershteyn, PhD, Director of Discovery Research, will be presenting at the upcoming international conference “Neural Stem Cells to Neural Circuits” in Naxos, Sicily, on May 27. During Session 3: “Disease and Therapeutics,” Marina will present the latest progress Neurona has made in regenerative cell therapies aimed at treating neurological disorders. The session will also be chaired by Arnold Kriegstein, MD, PhD, co-founder of Neurona. We’re proud to see Marina bringing her expertise to this global conversation on brain science and innovation. #Neurona #Epilepsy #RegenerativeMedicine

Two Neurona team members will be presenting at this year’s Epilepsy Therapies & Diagnostics Development (ETDD) XVIII symposium on Thursday, May 29th at the Lansdowne Resort in Leesburg, Virginia. Minh Le, MD, Senior Medical Director, will speak during Session VI: Gene and Cell Based Therapies, at 10:20 AM. During his presentation, “GABAergic Interneuron Cell Therapy for Epilepsy: Updated Trial Results for NRTX-1001,” Minh will highlight the latest updates regarding our cell therapy for drug-resistant focal epilepsy. John Hixson, MD, Vice President of Clinical Development, will present during Session VII: Devices at 11:50 AM. His talk, “Patient Apps: How Helpful Are They, How Often Are They Actually Used, Who Should They Be Designed For, How Can We Make Them Better?” will explore the role of digital tools in patient care and how they can be improved to better serve patients. Discover more about the symposium: https://xmrrwallet.com/cmx.petddtrials.com/

Neurona is happy to share to share that our CEO, Cory Nicholas, PhD, will be attending the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans, LA. Join Cory during "Translational Strategies for Cell and Gene Therapies in Inherited Neurotransmitter Disorders," a session taking place on Friday, May 16, from 8:00 to 9:45 AM in Room 291-292. His presentation, “Clinical Investigation of GABAergic Inhibitory Interneuron Cell Therapy for Drug-Resistant Epilepsy,” will highlight Neurona's innovative treatments for neurological disorders. Learn more about ASGCT 2025: https://xmrrwallet.com/cmx.plnkd.in/dHgkVjV #ASGCT2025 #Neurona #Epilepsy #RegenerativeMedicine